Publications

Comparison of Streptococcus pneumoniae and Haemophilus infuenzae,/i> susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: Five-year results for the SENTRY Antimicrobial Surveillance Program. by Gordon KA, Biedenbach DJ, Jones RN published in Diagn. Microbiol. Infect. Dis. 2003; 46 (4): 285-289

Over-expression of a novel RamA from Enterobacter cloacae confers carbapenem resistance in E. coli: Report from the SENTRY Antimicrobial Surveillance Program by Toleman MA, Jones RN and Walsh TR published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): 53-54

Antimicrobial susceptibility profile among ß-haemolytic Streptococcus spp. collected in the SENTRY Antimicrobial Surveillance Program – North America, 2001. by Biedenbach DJ, Stephen JM and Jones RN published in Diagn. Microbiol. Infect. Dis. 2003; 46 (4): 291-294

Influence of patient age on the susceptibility patterns of Streptococcus pneumoniae isolates in North America (2000 – 2001): Report from the SENTRY Antimicrobial Surveillance Program. by Jones RN, Biedenbach DJ and Beach ML published in Diagn. Microbiol. Infect. Dis. 2003; 46 (1): 77-80

Quinupristin/dalfopristin resistance in Streptococcus pneumoniae: Novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY Antimicrobial Surveillance Program. by Jones RN, Farrell DJ and Morrisey I published in Antimicrob. Agents Chemother. 2003; 47 (8): 2696-2698

Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: Prevalence results from the SENTRY Antimicrobial Surveillance Program. by Biedenbach DJ, Jones RN published in Diagn. Microbiol. Infect. Dis. 2003; 46 (1): 55-61

Distribution of fsr among Enterococcus faecalis isolates from the SENTRY Antimicrobial Surveillance Program. by Jones RN, Deshpande LM published in J. Clin. Microbiol. 2003; 41 (8): 4004-4005

Geographic variations and trends in antimicrobial resistance among Enterococcus faecalis and Enterococcus faecium in the SENTRY Antimicrobial Surveillance Program (1997 – 2000). by Mutnick AH, Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2003; 46 (1): 63-68

Evolution of an integron carrying blaVIM-2 in Eastern Europe: Report from the SENTRY Antimicrobial Surveillance Program. by Walsh TR, Toleman MA, Hryniewicz W, Bennett PM and Jones RN published in J. Antimicrob. Chemother. 2003; 52 (1): 116-119

Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: Comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program (2000). by Gordon KA, Jones RN and The SENTRY Participant Groups (Europe, Latin America, North America) published in Diagn. Microbiol. Infect. Dis. 2003; 45 (4): 295-301

Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centers: Five year report of the SENTRY Antimicrobial Surveillance Program (1997-2001). by Andrade SS, Jones RN, Gales AC and Sader HS published in J. Antimicrob. Chemother. 2003; 52 (1): 140-141

Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: Report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000). by Rennie RP, Jones RN, Mutnick AH and The SENTRY Program Study Group (North America) published in Diagn. Microbiol. Infect. Dis. 2003; 45 (4): 287-293

Resistance to ß-lactams among blood isolates of Salmonella spp. in European hospitals: Results from the SENTRY Antimicrobial Surveillance Program 1997-98. by Tzouvelekis LS, Lukova V, Tassios PT, Fluit AC, Jones RN and Legakis NJ published in Clin. Microbiol. Infect. 2003; 9 (2): 149-152

Linezolid resistance since 2001: SENTRY Antimicrobial Surveillance Program. by Mutnick AH, Enne V and Jones RN published in Ann. Pharmacol. 2003; 37 (6): 769-774

Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: Results of the SENTRY Antimicrobial Surveillance Study (2000). by Hoban DJ, Biedenbach DJ, Mutnick AH and Jones RN published in Diagn. Microbiol. Infect. Dis. 2003; 45 (4): 279-285

Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18,569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001). by Jones RN, Sader HS, Beach ML published in Int. J. Antimicrob. Agents 2003; 22 (6): 551-556

Initial description of the L22 mutation responsible for quinupristin/dalfopristin resistance in Streptococcus pneumoniae: Case reports from the SENTRY Antimicrobial Surveillance Program. Abstr. P1548. by Jones RN, Farrell D, Morrissey I on Behalf of the SENTRY Participants Group published in Clin. Microbiol. Infect. 2003; 9 (Suppl 1): 377

Comparative activity of garenoxacin (BMS284756), a novel desfluoroquinolone, tested against 8,331 isolates from community-acquired respiratory tract infections: North American results from the SENTRY Antimicrobial Surveillance Program (1999-2001). by Jones RN, Biedenbach DJ published in Diagn. Microbiol. Infect. Dis. 2003; 45 (4): 273-278

Antimicrobial susceptibility patterns of Beta-hemolytic and viridans group streptococci: Report from the SENTRY Antimicrobial Surveillance Program (1997-2000). by Gordon KA, Beach ML, Biedenbach DJ, Jones RN, Rhomberg PR and Mutnick AH published in Diagn. Microbiol. Infect. Dis. 2002; 43 (2): 157-162

Spectrum and potency evaluation of a new oxazolidinone, linezolid: Report from the SENTRY Antimicrobial Surveillance Program, 1998-2000. by Mutnick AH, Biedenbach DJ, Turnidge JD and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 43 (1): 65-73

Antimicrobial activity of broad-spectrum agents tested against Gram-negative bacilli resistant to ceftazidime: Report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). by Jones RN, Varnam DJ published in Diagn. Microbiol. Infect. Dis. 2002; 44 (4): 379-382

Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. by Pfaller MA, Diekema DJ, Jones RN, Messer SA and Hollis RJ published in J. Clin. Microbiol. 2002; 40 (3): 852-856

Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from blood stream infections in Latin American medical centers. by Sader HS, Jones RN, Andrade-Baiocchi S, Biedenbach DJ and The SENTRY Participants Group (Latin America) published in Diagn. Microbiol. Infect. Dis. 2002; 44 (3): 273-280

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000. by Pfaller MA, Messer SA, Hollis RJ and Jones RN published in Antimicrob. Agents Chemother. 2002; 46 (4): 1032-1037

Skin and soft tissue infections in Latin American medical centers: Four-year assessment of the pathogen frequency and antimicrobial susceptibility patterns. by Sader HS, Jones RN, Silva JB and The SENTRY Participants Group (Latin America) published in Diagn. Microbiol. Infect. Dis. 2002; 44:281-288

Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: Report from the SENTRY Antimicrobial Surveillance Program. by Jones RN, Della-Latta P, Lee LV and Biedenbach DJ published in Diagn. Microbiol. Infect. Dis. 2002; 42 (2): 137-139

Urinary tract infection trends in Latin American hospitals: Report from the SENTRY Antimicrobial Surveillance Program (1997-2000). by Gales AC, Sader HS, Jones RN and The SENTRY Participants Group (Latin America) published in Diagn. Microbiol. Infect. Dis. 2002; 44 (3): 289-299

BMS284756 (formerly T-3811, a des-fluoroquinolone) potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Programme (2000). by Gordon KA, Pfaller MA and Jones RN. published in J. Antimicrob. Chemother. 2002; 49 (5): 851-855

Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia in Latin America: Frequency of occurrence and antimicrobial susceptibility profile: Results from the SENTRY Antimicrobial Surveillance Program (1997-2000). by Gales AC, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 44 (3): 301-311

Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): Correlations of results from disk diffusion, Etest and reference dilution methods. by Deshpande LM, Fix AM, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 42 (4): 283-290

Pathogen occurrence and antimicrobial resistance trends among urinary tract infection isolates in the Asia-Western Pacific region: Report from the SENTRY Antimicrobial Surveillance Program, 1998-1999. by Turnidge J, Bell J, Biedenbach DJ and Jones RN published in Int. J. Antimicrob. Agents 2002; 20 (1): 10-17

Prevalence of extended spectrum β-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: Regional results from SENTRY Antimicrobial Surveillance Program (1998-99). by Bell JM, Turnidge JD, Gales AC, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 42 (3): 193-198

Molecular characterization of SPM-1, a novel metallo-beta-lactamase isolated in Latin America: Report from the SENTRY Antimicrobial Surveillance Programme. by Toleman MA, Simm AM, Murphy TA, Gales AC, Biedenbach DJ, Jones RN and Walsh TR published in J. Antimicrob. Chemother. 2002; 50 (5): 673-679

Impact of modified nonmeningeal Streptococcus pneumoniae interpretive criteria (NCCLS M100-S12) on the susceptibility patterns of five parenteral cephalosporins: Report from the SENTRY Antimicrobial Surveillance Program (1997 to 2001). by Jones RN, Mutnick AH and Varnam DJ published in J. Clin. Microbiol. 2002; 40 (11): 4332-4333

In vitro assessment of gatifloxacin spectrum and potency tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from the Asia-Western Pacific component of the SENTRY Antimicrobial Surveillance Program (1998-1999). by Bell JM, Turnidge JD, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 43 (4): 315-318

Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: Report from the SENTRY Antimicrobial Surveillance Program (2000). by Kirby JT, Mutnick AH, Jones RN, Biedenbach DJ, Pfaller MA and The SENTRY Participants Group published in Diagn. Microbiol. Infect. Dis. 2002; 43 (4): 303-309

Geographic variations in activity of broad-spectrum beta-lactams against Pseudomonas aeruginosa: Summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000). by Jones RN, Kirby JT, Beach ML, Biedenbach DJ and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2002; 43 (3): 239-243

Antimicrobial susceptibilities of H. influenzae and M. catarrhalis causing lower respiratory tract infections: SENTRY Antimicrobial Surveillance Program, Europe 2000. Abstr. P1109. by Loza E, Canton R, Morosini MI, Jones RN, Baquero F and The SENTRY Participants Group published in Clin. Microbiol. Infect. 2002; 8 (Suppl 1):250-251

Epidemiology of antibiotic resistance of bacterial pathogens from intensive care units: The SENTRY Surveillance Program in Europe 2000. by Rodriguez-Villalobos H, Jones RN, Struelens MJ published in Clin. Microbiol. Infect. 2002; 8 (Suppl 1):196-197

Antimicrobial resistance trends in community-acquired respiratory tract pathogens in the Western Pacific Region and South Africa: Report from the SENTRY Antimicrobial Surveillance Program (1998-1999) including an in vitro evaluation of BMS284756. by Bell J, Turnidge J, Jones RN and SENTRY Regional Participants Group published in Int. J. Antimicrob. Agents 2002; 19 (2): 125-132

Comparative activity of gatifloxacin against S. pneumoniae, H. influenzae, and M. catarrhalis before (1997-99) and during (2000) the clinical release in North America (NA): A SENTRY Antimicrobial Surveillance Program Report, abstr P7. by Jones RN, Pfaller MA, and the SENTRY Participants Group. published in J. Antimicrob. Chemother. 2001; 47 (Suppl S2): 18

Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin? Report from The SENTRY Antimicrobial Surveillance Program (1997-99). by Jones RN and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2001; 39: 237-243

Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): More alike than different! by Jones RN, Beach ML and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2001; 41 (3): 161-163

Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. by Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M and Jones RN. published in Clin. Infect. Dis. 2001; 32 (Suppl 2): S81-S93

BMS284756 potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (2000). Abstr P40. by Gordon KA, Pfaller MA, Jones RN, Sader HS, Biedenbach DJ, Beach ML and the SENTRY Participants Group. published in J. Antimicrob. Chemother. 2001; 47 (Suppl 1): S26-S27

Antimicrobial susceptibility testing of clinical isolates of Bordetella pertussis from northern California: Report from the SENTRY Antimicrobial Surveillance Program. by Gordon KA, Fusco J, Biedenbach DJ, Pfaller MA and Jones RN. published in Antimicrob. Agents Chemother. 2001; 45 (12): 3599-3600

Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY Antimicrobial Surveillance Program medical centers in Latin America (1999). by Gales A, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2001; 45 (5): 1463-1466

Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: Geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). by Gales AC, Jones RN, Forward KR, Linares J, Sader HS and Verhoef J published in Clin. Infect. Dis. 2001; 32 (Suppl 2): S104-S113

Pathogen frequency and resistance patterns in Brazilian hospitals: Summary of results from three years of the SENTRY Antimicrobial Surveillance Program. by Sader HS, Gales AC, Pfaller MA, Mendes RE, Zoccoli C, Barth A and Jones RN published in Braz. J. Infect. Dis. 2001; 5 (4): 200-214

Characterization of Pseudomonas aeruginosa isolates: Occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. by Gales AC, Jones RN, Turnidge J, Rennie R and Ramphal R published in Clin. Infect. Dis. 2001; 32 (Suppl 2): S146-S155